PHD, Kent State University, 2025, College of Arts and Sciences / School of Biomedical Sciences
Aortic valve stenosis (AS) is a progressive, life-threatening condition characterized by fibro-calcific remodeling of the aortic valve, leading to obstruction of blood flow and impaired cardiac function. Despite its increasing prevalence, no pharmacological therapy currently exists to halt or reverse the disease, highlighting a critical need for novel, non-invasive interventions. This dissertation investigates the therapeutic potential of exosomes derived from NAMPT-overexpressing mesenchymal stem cells (NAMPT-Exo) in mitigating AS and elucidates the underlying mechanisms of action.
Using our newly developed endothelial cell-specific CXCR4 knockout (EC CXCR4 KO) induced AS mouse model, we demonstrate the therapeutic potential of NAMPT-Exo in mitigating AS. NAMPT-Exo treatment in EC CXCR4 KO mice significantly attenuated AS progression, reduced valvular calcification and thickening, and improved cardiac function, as shown by echocardiography and histological analyses. Mechanistic studies further revealed that NAMPT-Exo treatment modulates endothelial-to-mesenchymal transition (EndMT), a key contributor to AS pathogenesis. Additionally, we found that miR-146a-3P expression was significantly elevated in cardiac endothelial cells of AS mice, while exosome treatment effectively reduced its levels.
These findings provide strong evidence that NAMPT-enriched MSC-derived exosomes represent a novel, cell-free therapeutic strategy for aortic valve stenosis and miR146a-3P may play an essential role in the disease development and progression.
Committee: William Chilian (Committee Member); Feng Dong (Advisor)
Subjects: Biomedical Research; Pharmacology